Dr Feng received his Ph.D in organic chemistry from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, and was trained as a postdoctoral fellow at the University of Michigan School of Pharmacy, USA.

He has worked in a few scientific institutions and new drug development companies, such as Egret Pharma (Shanghai) Ltd., Taub Institute of Columbia University Medical Center, Sandia, etc. and held the positions of Executive Director, Director of Medicinal Chemistry, the head of new drug preclinical development, and General Manager.

More than 10 years of experience in preclinical development programs (hit to lead to PCC to IND) for new drugs in antineoplastic, diabetic, cardiovascular, anticoagulant and other fields, and contributed to advance several compound candidates to the clinical stage, including SGLT2 inhibitor Bexagliflozin and JNK1 inhibitor CC-90001.

Over 20 years of experience in medicinal chemistry, synthetic chemistry, clinical development of new drugs, and project management.

Dr Xu received her PhD in Biochemistry from University of Leeds and completed her postdoc training in Proteomics and Bioanalysis, School of Pharmacy, University of Nottingham in UK.

Worked for a few UK CROs Covance and Concept Life Science, BioDuro-Sundia and Medicilon as Director/Executive Director of DMPK.

She brings Leadingtac18+ years of experience in bioanalysis, drug metabolism, proteomics and GxP project management.

Dr Ye completed his Ph.D in organic chemistry from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. Prior to joining Leadingtac, he worked at the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, and the University of Wisconsin-Madison School of Pharmacy as an assistant and associate researcher. He expands the company repertoire of R&D capacity and familiar with the R&D process of small molecule innovative drugs (Kinase inhibitors and PROTACs). He was awarded the 2022 Shanghai Pujiang Talent Program.